【Biosens Bioelectron】四川大学陈飘飘|40分钟完成无创检测！科学家开发3.6 ag/mL超灵敏荧光纳米免疫机器，膀胱癌诊断AUC达0.93
【Biosens Bioelectron】四川大学陈飘飘|40分钟完成无创检测！科学家开发3.6 ag/mL超灵敏荧光纳米免疫机器，膀胱癌诊断AUC达0.93
文章标题：Cascaded confinement-encapsulated fluorescence nano-immunomachine for noninvasive urinary monitoring of bladder cancer
文章作者：Shunyu Gao, Pengjun Jiang, Xiaoju Liu, Jia Wang, Qianli Lin, Yunjin Bai, Piaopiao Chen
文章概要
本文针对膀胱癌无创监测中传统检测方法步骤繁琐、基质干扰大等瓶颈，构建了一种级联约束限制的量子点封装DNA纳米免疫机器。研究团队利用可编程DNA自组装与苯乳酸诱导的纳米框凝练，实现了高密度量子点的稳定封存与低背景信号。该平台在特异性抗体修饰后，能够在一管式混合体系中快速识别膀胱癌特异性核基质蛋白4，并在40分钟内触发结构解组装与荧光信号恢复。该方法实现了低至3.6 ag/mL的检出限，并在72例临床尿液样本测试中展现出0.93的AUC诊断曲线下面积，为膀胱癌的无创诊断与术后复发动态监测提供了高效便捷的新策略。
Scheme 1. Schematic illustration of the fluorescence nano-immunomachine for one-pot detection of BLCA-4.
引言
膀胱癌是泌尿系统最常见的恶性肿瘤之一，其高复发率要求患者进行终身严密的术后随访。目前临床上诊断与监测的金标准仍为膀胱镜检查，但作为一种创伤性操作，它容易给患者带来明显的痛苦与不适，极大地降低了患者的随访依从性。尿液细胞学与传统影像学虽然实现了无创，但对低级别病变或微小病灶的检测灵敏度普遍偏低。鉴于尿液直接接触膀胱病变区域，尿液液态活检成为无创监测的理想途径，其中膀胱癌特异性核基质蛋白4（BLCA-4）被证实是极具临床潜力的生物标志物。
然而，目前针对BLCA-4的检测主要依赖传统酶联免疫吸附试验，该过程包含多次繁琐的洗涤与长时间孵育，且容易受到复杂尿液基质的背景干扰。尽管均相免疫分析能够免去分离步骤，但其敏感度不足且易受基质影响。DNA纳米技术凭借其优异的序列可编程性与结构可调控性，为整合分子识别与信号转导提供了可能。结合具有高亮度和高光稳定性的碲化镉量子点，研究团队提出了级联约束策略，通过充填分子诱导DNA网络紧密凝练，有效阻止荧光渗漏，从而构建出兼具高灵敏度与一键式简便操作的无创尿液检测平台。
Fig.1 PLA@DNS construction and characterization. (a) Schematic illustration of PLA@DNS formation. (b-d) TEM characterization of the assembled nanostructures. (e-g) AFM images of assembled nanostructures. (h-i) DLS profiles depicting hydrodynamic size evolution during assembly (h) and with PLA concentration (i). (j) Zeta potential analysis of nanostructures. (k) Representative TEM images of Y-shaped NS treated with different PLA concentrations. (l) Agarose gel electrophoresis validating the programmed assembly process. Error bars represent the standard deviation of three independent measurements.
主要实验及结论
研究团队首先系统探究了充填分子介导的DNA纳米球形成及其对量子点的封存机制。如图1所示，三条具有互补黏性末端的生物素化DNA单链首先退火自组装形成三叉状Y型纳米单元，随后进一步长程交联形成网状结构，构成了第一级空间约束。在引入苯乳酸作为分子填充剂后，非共价协同相互作用驱使松散的DNA网络凝练成高度均匀且紧密的球形纳米结构。透射电子显微镜与原子力显微镜清晰展示了这一从网状到紧密球形的形貌演变过程，动态光散射与凝胶电泳实验也同步证实了纳米球在苯乳酸作用下的凝练收缩。如图2所示，将碲化镉量子点与DNA网络共组装，可成功形成核壳结构的量子点纳米球，其元素分布证实量子点被稳定限制在内部核心。值得注意的是，苯乳酸表现出优异的光学兼容性，不会对量子点产生淬灭，而封存过程带来的空间限制则使体系处于低背景荧光状态，同时该纳米球在不同酸碱度环境和储存条件下均表现出良好的物理化学稳定性。
Fig.2 PLA-mediated construction of QDs-encapsulated DNA nanospheres and evaluation of encapsulation performance. (a) Schematic illustration of QDs@DNS formation. (b, c) TEM images of free QDs-570 (b) and TEM-derived particle size distribution (c). (d) TEM images of QDs@DNS. (e) UV-vis absorption spectra of free QDs-570 and QDs@DNS. (f) Fluorescence responses of QDs-570 in the presence of different molecular fillers. (g) HAADF-STEM images and corresponding elemental mapping of QDs@DNS. (h) Fluorescence spectra of free QDs-570 and QDs@DNS. (i) Intra-day repeatability of QDs@DNS fluorescence measured across ten independent tube tests. (j) Fluorescence stability of QDs@DNS under different pH conditions. (k) Fluorescence stability of QDs@DNS during storage. Error bars represent the standard deviation of three independent measurements.
在完成基础纳米结构的构建后，研究团队将抗BLCA-4抗体固定在纳米球表面，形成了功能化的纳米免疫机器，如图3及方案1所示。当体系中加入目标蛋白BLCA-4时，特异性的抗原抗体结合事件会引起局部结构应力，打破苯乳酸凝练的DNA架构，促使纳米球发生解组装并释出封闭的量子点，引起荧光信号的强劲恢复。透射电镜观察显示，靶标分子作用后原先紧密的球形结构发生破坏与碎裂，动态光散射测得的粒径显著减小，电位与凝胶电泳分析也一致印证了靶标诱导的解组装过程，证明了该系统作为靶标响应型荧光开关的可行性。
Fig.3 (a) Schematic workflow for preparing QDs@DNS@Ab and BLCA-4 incubation to induce nanostructure disassembly. (b) Fluorescence measurement. (c) DLS analysis. (d) Zeta potential measurement. (e-f) TEM characterization of QDs@DNS@Ab incubation with BLCA-4. (g) Agarose gel electrophoresis analysis. Error bars represent standard deviations from three measurements.
研究团队进一步对检测平台的分析性能进行了系统优化与评估。如图4所示，在优化后的苯乳酸浓度和50,000倍尿液稀释条件下，体系荧光强度与BLCA-4浓度的对数值在10至50,000 ag/mL范围内呈现出良好的线性关系，计算得到的检出限低至3.6 ag/mL。交叉反应实验表明，尿素、常见金属离子及其他尿液蛋白质均不会引发显著的荧光恢复，证实了平台的高特异性。在真实尿液加标回收实验中，该方法的回收率保持在98%至103%之间，表明大幅度的样品稀释配合离心预处理能够有效消除内源性色素、红细胞及蛋白质带来的干扰，保障了复杂生物基质中的测量准确性。
Fig.4 Analytical performance of the QDs@DNS@Ab-based BLCA-4 detection platform. (a) Schematic illustration of the sensing mechanism. (b) Fluorescence spectra at various BLCA-4 concentrations. (c-d) Peak fluorescence intensity versus BLCA-4 concentration with linear fitting curves. (e) Interference evaluation with urinary proteins and metal ions. (f) Schematic illustration of the spike-and-recovery assay. (g) Signal differences at different dilution ratios. (h) Recovery rates of BLCA-4. Error bars were calculated from three independent measurements and represented standard deviations.
Fig.5 Clinical validation of the QDs@DNS@Ab fluorescence sensing detection platform for urine BLCA-4. (a) Schematic illustration of the clinical sample detection workflow. (b, c) Fluorescence responses (b) and heatmap (c) of urine samples from healthy controls (n = 20), disease controls with non-bladder cancer urinary disorders (n = 22), and patients with bladder cancer (n = 30). (d) Corresponding box plot comparing urinary BLCA-4 fluorescence responses. (e, f) ROC curve (e) and confusion matrix (f) for BLCA-4-based diagnosis. (g) Correlation between QDs@DNS@Ab fluorescence and ELISA-measured BLCA-4 levels. (h) Representative CT images of patients with bladder cancer. Statistical significance: ***P < 0.001 (Mann-Whitney U test). Error bars were derived from three separate measurements and denoted the standard deviations.
为了验证临床应用价值，研究团队收集了包含30例膀胱癌患者、20例健康对照以及22例非癌泌尿系统疾病对照在内的72例临床尿液样本进行实测。如图5所示，膀胱癌组的尿液荧光信号显著高于健康对照组与非癌疾病组，说明信号提升由肿瘤特异性引发而非普通炎性病变。受试者工作特征曲线分析显示，该平台区分肿瘤与非肿瘤对照的诊断曲线下面积（AUC）达到了0.93，诊断灵敏度为93.3%，特异性为90.5%，且检测结果与传统酶联免疫吸附试验测定值展现出高度的一致性。最后，研究团队对15例接受手术切除的患者进行了术前与术后的配对尿液检测。如图6所示，患者术后尿液中的信号相较于术前出现了显著下降，并恢复至接近健康人群的基线水平，其对手术治疗前后状态变化的辨识AUC达到0.96，充分表明该平台能够精准追踪术后生物标志物的清除情况。
Fig.6 Postoperative monitoring of urinary BLCA-4 using the QDs@DNS@Ab fluorescence-sensing platform. (a) Schematic illustration of urinary BLCA-4 detection for perioperative monitoring. (b) Fluorescence responses of urine samples. (c) Box plot comparing urinary BLCA-4 fluorescence signals. (d) Paired comparison of urinary BLCA-4 fluorescence signals. (e) ROC curve. (f) Confusion matrix. (g) Representative histopathological images of bladder cancer tissue. Data are presented as mean ± SD from triplicate measurements. Statistical significance was determined using the Mann-Whitney U test for independent-group comparisons and the Wilcoxon matched-pairs signed-rank test for paired preoperative and postoperative samples; ***P < 0.001. Error bars were derived from three separate measurements and denoted as standard deviations.
总结及展望
本研究成功构建了一种基于级联约束策略的自组装荧光纳米免疫机器，实现了对尿液中膀胱癌标志物BLCA-4的单管式、免洗涤超灵敏检测。该平台将复杂的分子识别、结构调控与信号放大集成于一体，不仅将检测时间缩短至40分钟，还突破了传统均相分析灵敏度不足的瓶颈，在临床诊断与术后动态监测中均展现出卓越的准确性与实用性。
展望未来，该技术仍有进一步拓宽与升华的空间。在材料层面，未来可探索更多类型的分子填充剂以调控纳米球的解聚动力学与荧光响应速率；在应用拓展上，该模块化抗体修饰体系有望推广至其他肿瘤标志物或与核酸标志物实现联合检测，以提高多维度分子诊断覆盖率；在临床转化方面，仍需开展更大规模、多中心的临床研究以验证其在不同病理分期及亚型中的泛化能力，并结合冷干保存等技术提升试剂盒的长期储存稳定性，推进便携式现场即时检测设备的开发与落地。
文章分享
如果这篇文章对你有帮助，欢迎分享给更多人！